

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 15 (2005) 4650

Publisher's Note

Announcing New European Regional Editor for *Bioorganic & Medicinal Chemistry Letters*

Elsevier is pleased to announce the appointment of Professor Stephen Neidle, who takes over from Professor Léon Ghosez as Regional Editor for Europe of *Bioorganic & Medicinal Chemistry Letters* on 1 September 2005.

Stephen Neidle is Professor of Chemical Biology at The School of Pharmacy, University of London, UK, where he also directs the Cancer Research UK Biomolecular Structure Group. He was educated at Imperial College, London, where he graduated in chemistry and then proceeded to do his Ph.D. thesis on crystallographic studies of natural products and antibiotics. After a period as an ICI Fellow, he joined the Biophysics Department at King's College. He was appointed as one of the first Cancer Research Campaign Career Development Awardees, becoming a Life Fellow on moving to the Institute of Cancer Research. In 1990, he was appointed to the Chair of Biophysics at the Institute of Cancer Research, where he was academic dean from 1997 to 2002. He moved to the new Chair of Chemical Biology at the School of Pharmacy in 2002.

Professor Neidle's research interests are primarily in nucleic acid structure and recognition by small molecules and in exploiting this information for the rational design of new anticancer agents. In recent years this has emphasised two principal classes of molecules: G-quadruplexes and duplex DNA. Together with colleagues at the University of Texas, he pioneered the concept of the selective targeting of telomeric DNA with small molecules that stabilise G-quadruplex formation at the telomere and inhibit the action of the enzyme telomerase, which is up-regulated in the majority of human cancers.



Professor Stephen Neidle Regional Editor for Europe Bioorganic & Medicinal Chemistry Letters

More recently this work has led him and his group to the design of a new class of anticancer molecules, telomere targeting agents, which are currently in pre-clinical development.

Starting 1 September 2005, papers from Europe should be submitted to Professor Neidle via the journal's online submission page at www.ees.elsevier.com/bmcl.

Whilst welcoming the new editor, we would like to take this opportunity to express our gratitude to Professor Léon Ghosez and his editorial office for their dedication and contribution to the journal during 13 years of service.